Resverlogix provides update on BETonMACE phase 3 epigenetics trial
Resverlogix announced that all patients active in BETonMACE, the Company’s event-based, phase 3 registration trial, recently completed their last study visits on treatment. Final, follow-up safety visits are progressing and are expected to be completed by July 4th, 2019. June 12, 2019